Cibus 2025 Q3 Earnings Sharp Net Loss Reduction Amid Revenue Decline

Cibus reported Q3 2025 earnings with a 63.1% revenue drop to $615,000, missing estimates by 43.58%, while narrowing net losses by 87.9% to $24.3M. The company reaffirmed its 2026 guidance, targeting $30M in annual net cash usage and Latin American herbicide trait launches by year-end.

Revenue

Total revenue fell sharply to $615,000 in Q3 2025, a 63.1% decline from $1.67M in the prior-year period, driven by timing of partner-funded program activities.

Earnings/Net Income

The company narrowed its net loss to $24.3M, a 87.9% improvement from $201.5M in 2024 Q3. Earnings per share improved from a loss of $7.63 to $0.44, representing a 94.2% reduction. The 94.2% improvement in EPS from $7.63 to $0.44 highlights effective cost management and operational efficiency.

Post-Earnings Price Action Review

Cibus shares fell 5.30% on the day of the earnings report, edged down 0.40% for the week, and dropped 14.97% month-to-date. A 30-day buy-and-hold strategy post-earnings has delivered a -71.2% cumulative return over three years, averaging -24.4% annually—a stark underperformance relative to the broader market. This suggests the strategy remains unviable for CBUS.

CEO Commentary

Interim CEO Peter Beetham highlighted seven rice customer agreements covering 5–7 million acres, with potential $200M+ annual royalties. Regulatory progress in the UK, Ecuador, and California, alongside biofragrance pilot success, underscores optimism for 2027 Latin American commercialization and 2026 biofragrance revenue.

Guidance

Cibus targets herbicide trait delivery to Latin American customers by Q4 2025, field trials by year-end, and $30M annual net cash usage by 2026. Regulatory milestones in the UK and Ecuador, plus HT2 trait stackings in canola, aim to support global expansion.

Additional News

Cibus secured seven rice customer agreements, expanding access to 5–7 million acres with potential $200M+ annual royalties. Regulatory approvals in the UK and Ecuador advanced gene-edited rice planting and trait equivalence determinations, bolstering market access. A partnership with AgVayā aims to enter India’s rice market via seed company collaborations, targeting 2030–2032 launches.